Avidity biosciences plans first bla submission and accelerates commercialization preparations for three rare muscle disease programs in 2025

Accelerated approval path confirmed for del-zota; biologics license application (bla) submission planned for year end 2025   on track to complete enrollment in del-desiran harbor tm phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025    eric mosbrooker expands role to chief commercial officer; charles calderaro iii, chief technical officer, and kat lange, chief business officer, join as company prepares for global commercialization and continued pipeline expansion   avidity to present at 43rd annual j.p. morgan healthcare conference on tuesday, january 14 san diego , jan. 8, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced its progress and planning for a transformational year in 2025.
RNA Ratings Summary
RNA Quant Ranking